Edition:
India

People: Exact Sciences Corp (EXAS.OQ)

EXAS.OQ on NASDAQ Stock Exchange Capital Market

106.87USD
1:30am IST
Change (% chg)

$2.46 (+2.36%)
Prev Close
$104.41
Open
$104.54
Day's High
$107.55
Day's Low
$104.50
Volume
349,146
Avg. Vol
538,112
52-wk High
$123.94
52-wk Low
$53.09

Stenhouse, Mark 

Mr. Mark Stenhouse is President, Cologuard of the company. Mr. Stenhouse has served as President, Cologuard since April 2018. Prior to joining Exact, Mr. Stenhouse worked for over 25 years at Abbott Laboratories (NYSE: ABT) and AbbVie, Inc. (NYSE: ABVV), including in a number of executive and managerial positions within its U.S. Immunology division. Most recently, from October 2016 until March 2018, Mr. Stenhouse served as Vice President, U.S. Immunology, where Mr. Stenhouse developed AbbVie's U.S. expansion into the immunology marketplace. From April 2010 until September 2016, Mr. Stenhouse served as Vice President and Vice President/General Manager, U.S. Immunology—Gastroenterology Franchise, where Mr. Stenhouse led a successful turnaround of the franchise, including approval of HUMIRA for treatment of Ulcerative Colitis. From September 2006 through March 2010, Mr. Stenhouse held various senior management, marketing and sales positions within Abbott Laboratories' U.S. Immunology division. Mr. Stenhouse earned a bachelor's degree in business administration from College of Charleston.

Basic Compensation

Total Annual Compensation, USD 660,625
Restricted Stock Award, USD 2,910,000
Long-Term Incentive Plans, USD --
All Other, USD 291,631
Fiscal Year Total, USD 3,862,260

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Kevin Conroy

6,992,000

Jeffrey Elliott

1,983,860

Mark Stenhouse

3,862,260

D. Scott Coward

2,085,310

Graham Lidgard

2,084,980

Ana Hooker

--
As Of  31 Dec 2018